Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Sales | 1,635 | 1,201 | 445 | 251 | 1,279 |
| Gross Profit | 1,635 | 1,201 | 445 | 251 | 1,279 |
| Operating Expenses | 3,682 | 18,088 | 857 | 775 | 1,711 |
| Operating Income | -2,047 | -16,887 | -413 | -524 | -432 |
| Interest Expense | 13 | 25 | 910 | 348 | 546 |
| Other Income | -8,018 | -288 | 365 | -40 | -1,894 |
| Pre-tax Income | -10,077 | -17,200 | -958 | -912 | -2,872 |
| Net Income Continuous | -10,077 | -17,200 | -958 | -912 | -2,798 |
| Minority Interests | 0 | -36 | -22 | -4 | -196 |
| Net Income | $-10,077 | $-17,164 | $-936 | $-908 | $-2,602 |
| EPS Basic Total Ops | -2,355.97 | -2,546.75 | -215.98 | -215.98 | -1,210.92 |
| EPS Basic Continuous Ops | -2,230.11 | -2,552.02 | -214.72 | -207.26 | -1,241.65 |
| EPS Diluted Total Ops | -2,355.97 | -2,546.75 | -215.98 | -215.98 | -1,175.50 |
| EPS Diluted Continuous Ops | -2,230.11 | -2,552.02 | -214.72 | -207.26 | -1,217.32 |
| EBITDA(a) | $-2,047 | $-16,887 | $-413 | $-524 | $-432 |